Treatment Efficacy and Prognostic Factors for Huge HCC Based on Barcelona Clinic Liver Cancer Staging

• DOI: 10.7314/apjcp.2014.15.20.8823
• Publication Date: 2014-12-29T21:49:18Z
• Authors: Zhi-Ming Zhang; Yu-Mei Zhang; Sheng Gao; Wei-Ping Yuan; Yin-Nong Zhao; Bang-De Xiang; Fei-Xiang Wu; Guo-Bin Wu; Jian-Yong Liu
• Keywords: Liver Cancer

To explore the most appropriate treatment for patients with hepatocellular cancer (HCC)>10 cm by using Barcelona Clinic Liver Cancer (BCLC) classification.A total of 124 HCC undergoing surgery were selected. Disease-free survival (DFS), overall (OS) and prognostic factors respectively assessed.This study showed that cumulative 1-, 3-, 5-year rates 79.7%, 59.8% 41.6% in BCLC-A patients, 76.2%, 9.5% 0% BCLC-B 44.9%, BCLC-C respectively. The DFS 49%, 24.5% 9.1% 7.5%, No survived 1 year after surgery. Multivariate analysis indicated hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepatic metastasis, curative resection, tumor rupture pathologic differentiation independent factors.Surgery is effective safe HCC>10 sufficient hepatic reserve.